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Abstract Secondary hyperparathyroidism (sHPT) is a
frequent complication in patients with chronic kidney
disease (CKD) and a known contributor to the development
of vascular calcification and renal osteodystrophy (CKD–
BMD). Secondary hyperparathyroidism is also related to
increased cardiovascular mortality in CKD patients. With
the discovery that molecules can modulate the calcium-
sensing receptor (CaR) of the parathyroid gland, new
treatment options are now available to control sHPT.
Calcimimetics activate the CaR and—by increasing its
sensitivity to calcium—can effectively decrease parathyroid
hormone (PTH) secretion. Calcimimetic treatment with
cinacalcet has resulted in an effective lowering of PTH
levels in both animal and clinical studies. Most clinical
studies have been performed in dialysis patients, and only a
few studies have been carried out in patients with CKD
stage 3 & 4 and renal transplant patients. In haemodialysis
patients with sHPT, cinacalcet treatment could increase the
number of patients achieving National Kidney Foundation
Kidney Disease Outcomes Quality Initiative targets (PTH,
calcium, phosphate) compared to standard therapy. In stage
3 and 4 CKD patients, cinacalcet has been reported to
reduce PTH levels, however, at the expense of increasing
phosphate serum levels. Several small studies have reported
that calcimimetics reduced PTH levels and hypercalcaemia
after renal transplantation. In addition, two studies on
paediatric dialysis patients with sHPT reported effective
PTH lowering. This review summarizes recent clinical
studies with cinacalcet treatment in CKD patients.
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Background
Secondary hyperparathyroidism (sHPT) frequently develops
during stages 3 and 4 of chronic kidney disease (CKD3/4).
Increased serum levels of intact parathyroid hormone (PTH)
have been associated with cardiovascular calcifications,
morbidity and mortality in dialysis patients. Prolonged
hypocalcaemia, hyperphosphataemia, low calcitriol and
elevated FGF-23 levels all contribute to increased PTH
synthesis and secretion. Phosphate retention as well as
increased FGF-23 levels inhibit the activity of the 1α-
hydroxylase, which contributes to decreased calcitriol
synthesis and constitutes an additional indirect mechanism
by which they feed into elevated PTH synthesis. Moreover,
the numbers of calcium-sensing receptors (CaR) and vitamin
D receptors (VDR) are lower in CKD patients, resulting in a
decreased sensitivity of the parathyroid gland to both serum
calcium changes and calcitriol. The CaR is responsible for
calcium-mediated signalling in parathyroid cells and plays a
central role in the regulation of synthesis and secretion of
PTH. Calcimimetics activate the CaR by mimicking or
potentiating the inhibitory effects of extracellular calcium on
parathyroid cells (Fig. 1). This leftward shift in the set point
for calcium-regulated PTH secretion by calcimimetics leads
to a reduction in PTH secretion. Calcimimetic compounds
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can be either inorganic (e.g. Mg2+) or organic molecules
(e.g. spermine) or phenylalkylamine derivatives (e.g.
cinacalcet). Traditionally, secondary hyperparathyroidism
(sHPT) has been treated with calcium and vitamin D
therapy plus phosphate binders; however, with these
interventions, only a few patients achieved the targets—
especially all of the targets—of the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI). Thus, the introduction of cinacalcet as a
calcimimetic compound offers new therapeutic options to
control sHPT in CKD patients.
Studies of cinacalcet in dialysis patients with sHPT
Studies assessing biochemical endpoints
It has been possible to demonstrate the safety and efficacy
of cinacalcet treatment of sHPT in dialysis patients in
controlled trials despite standard therapy with active
vitamin D and phosphate binders as appropriate (Table 1)
[1–4]. Of note, cinacalcet treatment did not only result in a
marked decrease in serum PTH but also in significant
reductions in serum calcium, phosphate and the calcium–
phosphate product. A meta-analysis revealed an average
reduction in PTH of 290 pg/mL, in serum calcium of
0.85 mg/dL, in serum phosphate of 0.29 mg/dL and in the
calcium–phosphate product of 7.90 mg2/dL2 [5]. The early
decrease in serum calcium, phosphate and the calcium–
phosphate product may be interpreted as the analogue of a
“hungry bone” after parathyroidectomy, where the bone
avidly incorporates calcium and phosphate and thus lowers
serum calcium and phosphate levels. However, it is notable
that in a long-term study, cinacalcet did lead to persistent
reductions of the calcium–phosphate product [6] under
conditions when a “hungry bone” can no longer be
implicated.
A retrospective analysis could demonstrate that cinacalcet
treatment increased the percentage of patients achieving the
KDOQI targets [7]. In this study, data of three placebo-
controlled, double-blind, 26-week studies with similar
design were combined. A total of 1136 subjects on dialysis
were randomized to receive traditional therapy plus
cinacalcet or placebo. Cinacalcet intake was titrated from
30 mg to 180 mg per day. The number of patients achieving
both KDOQI targets for phosphate and calcium and PTH
levels below 300 pg/mL increased significantly from 6 to
41% [7]. The OPTIMA study confirmed these data in a
prospective fashion [8]. In this latter study, 552 patients
were randomized to conventional treatment or cinacalcet.
The primary endpoint, i.e. the proportion of patients with
mean PTH levels below 300 pg/mL, could be achieved in
71% of the patients in the cinacalcet group versus 22% in
the control group [8]. A recent Japanese study also
confirmed the effect of cinacalcet on PTH lowering but
reported a lower dosage of cinacalcet needed to achieve the
PTH target in that Asian population [9]. First results of the
ECHO study, a European observational study in 1800
haemodialysis patients with sHPT, confirmed the results of
the controlled studies with cinacalcet treatment [10]. After
12 months of treatment with cinacalcet, PTH levels could
be reduced by 49% and the calcium–phosphate product by
17%. Again, the dosage of cinacalcet necessary to achieve
this appeared to be lower than in the controlled studies,
with most patients ingesting 30 or 60 mg cinacalcet daily
[10].
Two studies investigated the effects of cinacalcet added
to low doses of vitamin D in dialysis patients. In the open-
label TARGET study, 444 haemodialyis patients were
treated with cinacalcet and around 80% of the patients
were on vitamin D treatment, which was reduced in the
second part of the study [11]. Cinacalcet plus low-dose
vitamin D treatment was able to improve KDOQI targets
[11]. Another study investigated the combination of
cinacalcet with a fixed low-dose vitamin D therapy versus
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Fig. 1 Calcimimetics act on the calcium-sensing receptor (CaR) by
mimicking and/or potentiating the effects of calcium. Increased serum
calcium (Ca2+) levels activate the CaR of the parathyroid cell, which
leads—via intracellular signalling mechanisms—to decreased para-
thyroid hormone (PTH) synthesis and secretion. Calcimimetics
potentiate the effect of serum calcium and thus can lower serum
calcium and serum phosphate (PO4) levels in dialysis patients with
secondary hyperparathyroidism. Note that calcimimetics can decrease
serum phosphate levels only in dialysis patients but not in patients
with stage 3 and 4 chronic kidney disease (CKD 3&4) or renal
transplant patients. There is also experimental evidence that calcimi-
metics can increase the numbers of both the CaR and vitamin D
receptors (VDR) in parathyroid cells
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vitamin D alone (where flexible dosing was allowed) in 173
dialysis patients (ACHIEVE) [12]. In this study, the fixed
combination of cinacalcet plus low-dose vitamin D resulted
in an effective PTH lowering when compared to vitamin D
alone. However, in both of the studies, no direct comparison
of cinacalcet without vitamin D versus cinacalcet plus
vitamin D was made. Thus, it can only be concluded that
cinacalcet plus vitamin D is a feasible therapeutic strategy,
but the advantage of vitamin D added to cinacalcet has yet to
be proven.
Side effects of cinacalcet are most commonly related to
gastrointestinal disturbances and include nausea, vomiting,
diarrhoea and loss of appetite. Cinacalcet treatment causes
only minimal changes in gut hormones [13]. Whether the
decrease in vasoactive intestinal peptide (VIP) or the
increase in substance P at 4 h after cinacalcet ingestion is
responsible for the unwanted symptoms remains to be
determined. Alternatively, these side effects may be related
to cinacalcet binding to the calcium-sensing receptor in the
gut, i.e. direct cinacalcet effects.
Studies assessing clinical endpoints
As increased PTH levels are associated with increased
mortality, it is of interest to determine whether cinacalcet
treatment can improve clinical outcomes. With the aim of
assessing the efficacy of cinacalcet treatment, Cunningham et
al. [14] performed a retrospective analysis of various
intervention studies that primarily looked at biochemical
parameters (see above). In this analysis, pooled data from
four randomized controlled studies were evaluated, and
several outcome parameters were measured in more than
1400 haemodialysis patients at 6–12 months: parathyroidec-
tomy, fractures, hospitalization, mortality and self-reported
quality of life. Cinacalcet treatment plus standard care led to
a significantly reduced rate of parathyroidectomies (−93%)
and fractures (−54%) when compared to the group with
standard care alone. While the number of all-cause hospital-
izations did not differ between the two groups, patients in the
cinacalcet group had significantly reduced cardiovascular
(CV)-related hospitalizations (−39%). However, this benefit
became most notable during the later, open-label phase of the
studies and when patient numbers had dropped markedly.
This outcome thus represents an interesting pilot observation,
which will require confirmation in adequate prospective
studies. In terms of quality of life, patients randomized to
cinacalcet treatment reported an improvement in physical
function but not in the other domains [14]. Finally, over the
course of the short-term observation, there was no significant
difference in mortality in the group treated with cinacalcet
compared to the standard treatment group.
Following these above pilot studies, the Evaluation of
Cinacalcet HCl Therapy to Lower CV Events (EVOLVE)
study was initiated. EVOLVE is a randomized placebo-
controlled trial investigating the effect of cinacalcet
treatment on mortality and CV events [15]. In this world-
wide phase 3 randomized, double-blind, controlled clinical
trial, approximately 3800 haemodialyis patients with sHPT
have been assigned to cinacalcet or placebo in addition to
traditional therapy. Recruitment finished in early 2008, and
the study, which is event-driven, is expected to last a further
2.5 years. The primary composite endpoint is time to all-
cause mortality or the first occurrence of a non-fatal CV
event (myocardial ischaemia or infarction, heart failure, or
peripheral vascular event). Cinacalcet will be titrated
between 30 and 180 mg/day based on PTH concentrations,
and flexible use of active vitamin D derivatives and phosphate
binders will be permitted in both treatment groups. The aim of
a second randomized world-wide trial is to investigate
whether cinacalcet can slow down the progression of coronary
artery calcification in haemodialysis patients (ADVANCE
trial=A randomizeD VAscular calcificatioN study to evaluate
the effects of CinacalcEt). In this study, approximately 330
haemodialysis patients will be investigated over the course of
1 year, with patients assigned to either cinacalcet in
combination with low-dose vitamin D or standard therapy.
Taken together, cinacalcet has been shown to reduce not
only PTH levels effectively but also to lower serum calcium
and phosphate levels in CKD patients on dialysis. Whether
these changes will lead to reduced morbidity or a survival
benefit in dialysis patients is currently under investigation.
Studies in paediatric dialysis patients with sHPT
As the problem of sHPT is not limited to adult CKD
patients, calcimimetics also provide a therapeutic option in
the treatment of sHPT in paediatric dialysis patients. Two
open-label single-arm studies reported in this issue of the
journal investigated cinacalcet treatment in nine and seven
paediatric patients with end stage renal disease (ESRD) and
sHPT, respectively [16, 17]. The young patients (range 7.5–
17.5 and 1.1–19 years, respectively) were both on haemo-
dialysis and peritoneal dialysis regimens. In these studies,
cinacalcet treatment resulted in a 61% and 79% decline of
serum PTH levels, respectively. This decrease in PTH
seems to be more pronounced in paediatric patients when
compared to adults (Table 1). The cinacalcet dosage was
therefore reduced to 0.25 mg/kg body weight in the second
study [17], which is significantly lower that the usual
starting dose of 30 mg in adults. It is possible that even
lower starting dosages than the suggested 0.25 mg/kg
should be considered (e.g. 0.15 mg/kg body weight).
Calcimimetics do have the potential to interfere with
growth during adolescence (epiphyseal chondrocytes express
the CaR). However, at least one experimental study was
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unable to find a significant effect of cinacalcet on longitudinal
growth in uremic rats [18]. Another concern associated with
treating adolescent children with calcimimetics is that lower
testosterone levels have been reported recently in adult
patients on cinacalcet treatment [19].
Taken together, cinacalcet seems to be equally effective
in children as in adults; however, studies investigating long-
term consequences of cinacalcet therapy in adolescents need
to be performed.
Studies of cinacalcet in CKD 3 and 4 patients
with sHPT
Since sHPT often develops in stages 3 and 4 of CKD, an
attractive option is to start cinacalcet treatment in earlier
stages with the aim of controlling sHPT effectively before
advanced or tertiary hyperparathyroidism develops. One
preliminary study reported that cinacalcet can efficiently
treat sHPT in CKD patients not receiving dialysis [20]. In
this double-blind placebo-controlled study, cinacalcet treat-
ment was evaluated in 54 patients with CKD 3 and 4.
Cinacalcet treatment decreased PTH levels by approximately
35% and lowered serum calcium levels by 7%, whereas the
levels of serum phosphate and the calcium–phosphate product
increased by approximately 10 and 7%, respectively [20]. A
larger double-blind randomized study with nearly 400 CKD
3 and 4 patients recently confirmed these results and reported
an effective reduction in serum PTH and calcium levels
while, again, phosphate levels increased with cinacalcet
treatment [21]. Whether such an increase in serum phosphate
levels bears a risk for vascular calcification, or other adverse
outcomes, remains to be determined.
Studies of cinacalcet in renal transplant patients
with persistent sHPT
Hyperparathyroidism frequently persists after successful
renal transplantation; in particular, pronounced phosphaturia
with resulting hypophosphataemia are frequent observations
early after renal transplantation. Oral or parenteral phosphate
replacement in such instances may contribute to intra-graft
calcifications, a recently recognized cause of inferior graft
survival [22]. Cinacalcet provides an attractive alternative
therapeutic option in this latter case, but also for patients
with persistent hyperparathyroidism long after transplanta-
tion. The results from eight small studies assessing the
off-label use of cinacalcet in a maximum of 18 transplant
patients were recently summarized by Chonchol and
Wüthrich [23]. In all of these studies, relatively low
cinacalcet doses were needed (average, 30–40 mg/day) to
control hyperparathyroidism. Therapy with cinacalcet led to
PTH and serum calcium decreases while phosphate serum
levels were mostly upregulated without adversely affecting
graft function [23]. As cinacalcet may interact with immu-
nosupressants, a recent study with 14 transplanted patients
investigated the effect of cinacalcet on serum levels of
cyclosporine, tacrolimus and mycophenolate [24]. Cinacalcet
treatment induced a 14% decrease in tacrolimus levels while
cyclosporine and mycophenolate levels were not significant-
ly altered. The level of the cyclosporine metabolite AM19
was increased by 9%, and this increase was paralleled by a
small but significant reduction in glomerular filtration rate
(GFR) [24]. Thus, immunosuppressant levels and graft
function need to be monitored closely when cinacalcet
treatment has been initiated or altered in transplanted
patients.
Other potential indications for cinacalcet
in CKD patients
In addition to the treatment of sHPT, cinacalcet may be
used to treat other clinical conditions in CKD patients. The
most commonly recommended approach to treating primary
hyperparathyroidism in symptomatic patients is parathy-
roidectomy. Even asymptomatic patients may be considered
for parathyroidectomy when they meet criteria, such as
young age, increased serum calcium levels, increased
urinary calcium excretion, reduced bone density or de-
creased renal function [25]. In a multicentre, randomized,
double-blind, placebo-controlled study with 78 patients,
cinacalcet normalized serum calcium and reduced PTH in
patients with primary hyperparathyroidism. As these effects
were maintained with long-term treatment, cinacalcet may
be an effective, non-surgical approach for the management
of primary hyperparathyroidism [26]. Very recently, a small
study on four patients was able to demonstrate that
cinacalcet can lower PTH levels after unsuccessful para-
thyroidectomy [27]. Another condition for which calcimi-
metics can be used is parathyroid carcinoma. In patients
with inoperable parathyroid carcinoma, cinacalcet was
shown to effectively lower serum calcium levels in about
two thirds of the patients [28]. In this study with 29
patients, PTH levels could only be slightly decreased;
however, this result demonstrates that calcimimetics offer a
therapeutic option for calcium lowering in patients with
parathyroid carcinoma when other treatment options fail.
Finally, the gastrointestinal, in particular colonic, expres-
sion of the CaR may be of therapeutic interest in completely
different clinical scenarios. Preliminary evidence shows that
the chemopreventive action of calcium and calcitriol in colon
cancer is mediated—at least in part—through the CaR [29]
and that receptor agonists were able to reverse cholera toxin
and shiga toxin-induced secretory diarrhoea [30]. Moreover,
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it has been shown in animal experiments that calcimimetics
may exert beneficial effects on blood pressure in uremia and
may ameliorate kidney damage in subtotally nephrectomized
rats [31–33]. Thus, in the future, clinical indications for
calcimimetics may reach far beyond the control of PTH
secretion.
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